Hostname: page-component-848d4c4894-ndmmz Total loading time: 0 Render date: 2024-05-10T19:22:24.966Z Has data issue: false hasContentIssue false
  • English
  • Français

Agents for the Treatment of Pseudomonas aeruginosa Infections

Published online by Cambridge University Press:  02 January 2015

Mark Eggleston
Mark Eggleston*
Affiliation:
Howard University, Washington, DC
*
PO Box 115, Wood-bridge, VA 22191
Get access Rights & Permissions [Opens in a new window]

Extract

Pseudomonas aeruginosa is the most common pathogen of Pseudomonas species. One of the most virulent organisms pathogenic to man, P aeruginosa can cause a variety of infections in humans. Despite the introduction of many new antimicrobial agents with enhanced activity against P aeruginosa, the high mortality rate associated with the organism over the past two decades continues.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 8 , Issue 9 , September 1987 , pp. 380 - 383
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Gessarci, C, Sur les colorations bleue el verle des linges a pansements. CH. Seances Acad Sci Serie D 1882;94:536.Google Scholar
2.Pollack, M, Pseudomonas aeruginosa, in Mandeli, GL, Douglas, KG Jr, Bennett, JE (eds): Principles and Practice of Infectious Diseases, ed 2. New York, John Wiley & Sons, 1979, pp 1236–1250.Google Scholar
3.Bodey, GP, Bolivar, R, Fainstein, V, et al: Infections caused by J Pseudomonas aeruginosa. Rev Infect Dis 1983;5:279–313.CrossRefGoogle Scholar
4.Nicas, TI, Iglewski, BH, The contribution of exoproducts lo virulence of Pseudomonas aeruginosa. Can J Microbial 1985;31:387.Google Scholar
5.Young, LS, The role of exotoxins in the pathogenesis of Pseudomonas aeruginosa infections. J Infect Dis 1980;142:626.Google Scholar
6.Pollack, M, The virulence of Pseudomonas aeruginosa. Rev Infect Dis 1984;6(suppl 3):S617.CrossRefGoogle ScholarPubMed
7.Centers for Disease Control: Nosocomial infection surveillance, 1980-1982. CDC Surveillance Summaries 1983;32:15–16SS.Google Scholar
8.Gerding, DN, Larson, TA, Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Am J Med 1985;79:1–7.CrossRefGoogle ScholarPubMed
9.University of Minnesota Hospitals: Clin Microbiol Lab Newsl 1984;9:1.Google Scholar
10.Holmes, KK, Clark, H, Silverblatt, F, et al: Emergence of resistance in Pseudomonas during carbenicillin therapy. Antimicrob Agents Chemother 1969;1970:391.Google Scholar
11.Platt, R, Ehrlich, SL, Alarin, J, et al: Moxalactam therapy of infections caused by cephalothin-resistant bacteria: Influence of serum inhibitory activity on clinical response: acquisition of antibiotic resistance during therapy. Antimicrob Agents Chemother 1981;20:351.Google Scholar
12.Winston, DJ, McGrattan, MA, liusuttil, RW, Imipenem therap J of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984;26:673.Google Scholar
13.Rubenis, J, Kozik, VM, Jackson, GG, Laboratory studies on genlamicin. Antimicrob Agents Chemother 1963;3:153.Google Scholar
14.Bundtzen, RW, Gerber, AU, Cohn, DL, et al: Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28.Google Scholar
15.Corrado, ML, Landesman, SH, Cherubin, CD, Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin and N. Formimidoyl Thicnamycin (MK 0787) against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1980;18:893.CrossRefGoogle Scholar
16.Eng, RH, Smith, SM, Cherubin, C, Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:42.Google Scholar
17.Lesar, TS, Rotschafer, JC, Strand, LM, et al: Gentamicin dosing errors with four commonly used nomograms. JAMA 1982;248:1190–1193.Google Scholar
18.Jackson, GG, Riff, LJ, Pseudomonas bacteremia: Pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971;124:185–191.Google Scholar
19.Noone, P, Parsons, TMC, Pattison, JR. et al: Experience in monitoring genlamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974;1:477–481.Google Scholar
20.Zaske, DE, Bootman, JL, Solem, LD, et al: Increased burn patient survival with individualized doses of genlamicin. Surgery 1982;91:142–149.Google Scholar
21.Moore, RD, Smith, CR, Lietman, PS, The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia, J Infect Dis 1984;149:443–448.CrossRefGoogle ScholarPubMed
22.Eliopoulos, GM, Moellering, RC, Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis 1982;4:282.Google Scholar
23.EORTC International Antimicrobial Therapy Project Group: Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978;137:14.Google Scholar
24.Reyes, MP, El-Khatib, MRBrown, WJ, et al: Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis 1979;140:192.CrossRefGoogle Scholar
25.Peterson, CD, Kaatz, BL, Angaran, DM, Ticarcillin and carbenicillin: A comparison. Drug Intel Clin Pharm 1977;11:482–486.Google Scholar
26.Phaneuf, D, Neu, HC, Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin and ticarcillin. Antimicrob Agents Chemother 1979;16:625–630.Google Scholar
27.Neu, HC, The new beta-lactamase stable cephalosporins. Ann Intern Med 1982;97:408–419.Google Scholar
28.Baltch, AL, Smith, RP, Combinations of antibiotics against Pseudomonas aeruginosa. Am J Med 1985;79:8–16.Google Scholar
29.Boerema, J, Boll, B, Muytjens, H, et al: Efficacy and safety of ciprofloxacin in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1985;16:212–217.Google Scholar
30.Wolff, M, Regnier, B, Fuldoss, C, et al: Penetration of pefloxacin into the CSF of patients with meningitis. Antimicrob Agents Chemother 1984;26:289–291.Google Scholar
31.Eton, LJ, Harvey, L, Hixon, DL, et al: Ciprofloxacin therapy of infections caused by J Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 1985;27:308–310.Google Scholar
32.Mehtar, S, Drabuy, Y, Blakemore, P, Ciprofloxacin in the treatment of infections caused by gentamicin-resistant gram-negative bacteria. Eur J Clin Microbiol 1986;5:248–251.CrossRefGoogle ScholarPubMed
33.Follath, F, Bindschedler, M, Wenk, M, et al: Use of ciprofloxacin in ihe treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:236–240.Google Scholar
34.Pennington, JE, Pseudomonas aeruginosa: Managinga virulent pathogen. Monograph from Eli Lilly and Company. New York, John Wiley & Sons Medical Group Company, 1987, pp 1–25.Google Scholar
35.Collins, MS, Roby, RE, Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa. Am J Med 1984;76:168.Google Scholar
36.Pennington, JE, Pier, GB, Small, GJ, Efficacy of intravenous immune globulin for treatment of experimental Pseudomonas aeruginosa pneumonia. J Crit Care 1986;1:4.Google Scholar